Hyperthermic intraperitoneal chemotherapy treats advanced cancers that have spread to the abdominal lining, specifically peritoneal carcinomatosis. This intensive therapy targets malignancies including ovarian, colorectal, gastric, and appendix cancers, alongside peritoneal mesothelioma and pseudomyxoma peritonei, by delivering heated drugs directly into the abdominal cavity after surgical tumor removal.
- Gastrointestinal cancers: Effectively targets stage 4 colon, rectal, and advanced stomach (gastric) cancers.
- Gynecologic malignancies: Primarily treats advanced or recurrent ovarian cancer to reduce recurrence risks.
- Rare pathologies: Specialized for appendiceal cancer, primary peritoneal cancer, and asbestos-linked peritoneal mesothelioma.
- Strict eligibility: Limited to patients whose cancer remains confined within the peritoneal cavity.
Bookimed Expert Insight: Spanish oncology centers often provide PIPAC alongside traditional HIPEC, offering a less invasive aerosolized alternative for patients with high-volume ascites. Dr. Alfonso García Fadrique at Hospital Vithas Valencia Turia leads specialized R&D into HIPEC quality standards, which is a critical differentiator when choosing a center for such complex 12-hour surgeries.
Patient Consensus: Patients often view this procedure as a decisive first-line attack rather than a last resort. Many emphasize that while the 2-month recovery is demanding, the potential for remaining disease-free for several years makes the intensive surgery worthwhile.